Interventional - Drug
Restless legs syndrome (RLS) affects 30% of dialysis patients and is associated with a decreased quality of life.
RLS is more common in patients with kidney disease compared to the general population, the pathophysiology is poorly understood, and current evidence for RLS in end stage renal disease (ESRD) patients is lacking.
The DISCO-RLS study aims to determine whether a fixed, low-dose combination therapy may be beneficial to target the multiple pathways implicated in the pathophysiology of RLS in individuals with kidney disease, while avoiding exposure to higher doses of medications that are associated with adverse events.
DISCO-RLS is a four-treatment crossover randomized controlled trial with a single blind double placebo run-in period.
Nephrology Research Fellow, David Collister, is also a key team member.Download Presentation PDF
Interventional - Drug
Single blind double placebo RCT
Michael Walsh is a Principal Investigator in the Renal research program at PHRI, and an Assistant Professor, Department of Medicine (nephrology), McMaster University. His research activities are in the areas of the treatment of patients who require dialysis, severe glomerular disease, and perioperative acute kidney injury. He has published more than 70 papers and two book chapters.
He holds a Kidney Research Scientist Core Education and National Training (KRESCENT) Program New Investigator award through CIHR and the Kidney Foundation of Canada. He’s received multiple Top Abstract awards from the Canadian Society of Nephrology, the Chalmers Prize from the Society for Clinical Trials, and the Detweiller Traveling Scholar Award from the College of Physicians and Surgeons of Canada.
Tara McCready, PhD, oversees a variety of collaborative programs at PHRI, and serves as Project Manager for PHRI research studies and registries.
She was recruited to PHRI as a Program Director for the Canadian Network and Centre for Trials Internationally (CANNeCTIN), a national network funded by the CIHR/CFI Clinical Research Initiative program to improve the prevention and treatment of cardiac and vascular diseases and diabetes.
Previously the Executive Director of the Canadian Maternal, Infant, Child and Youth Research Network, Tara holds a PhD in Biochemistry and a MBA in Technology Commercialization from the University of Alberta.
Back To Top